Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP)
Conditions
Interventions
Avitinib Maleate
Afatinib
+13 more
Locations
1
China
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
Guangzhou, Guangdong, China
Start Date
July 9, 2018
Primary Completion Date
December 30, 2022
Completion Date
December 30, 2024
Last Updated
December 6, 2022
NCT04165798
NCT06667908
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
Guangdong Association of Clinical Trials
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions